Core Viewpoint - Ark Health (06086) has observed a recent increase in its share price on the Hong Kong Stock Exchange as of September 12, 2025, following the announcement of its strategic initiatives and partnerships in the healthcare sector [1]. Group 1: Company Developments - The company has launched its proprietary "Xing Shi" large model, which serves as the foundation for five flagship applications, including AI medication assistant, AI health manager, AI doctor assistant, AI academic assistant, and AI search, aimed at enhancing clinical diagnostic support and personalized chronic disease management [1]. - Ark Health has formed a strategic partnership with Innovent Biologics to integrate its H2H digital health ecosystem with Innovent's weight management therapy pipeline, utilizing the "Xing Shi" model to provide personalized digital maintenance and adherence support for Innovent's Ma Shidu peptide in China's rapidly growing weight management market [1]. - The company has also entered into a strategic collaboration with Zhejiang Otsuka Pharmaceutical Co., combining its AI technology advantages with Otsuka's innovative drug portfolio to jointly develop comprehensive digital solutions covering drug support services, targeted patient outreach programs, and health education initiatives [1]. Group 2: Regulatory Confirmation - The board has confirmed that the information contained in the press release does not constitute inside information as defined under the Listing Rules and relevant securities regulations, and it is unaware of any reasons for the increase in share price or any information that needs to be disclosed to avoid creating a false market in its shares [2].
方舟健客：H2H 大会消息非内幕消息 不知股价上涨原因